- Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin.
- INT301 is based on the company's OMIT (oral mucosal immunotherapy) platform which enables the administration of the drug via a specialized toothpaste.
- Peanut allergy-related tickers: (NASDAQ:ANAB -1.3%)(AIMT +0.3%)(DBVT -0.8%)
Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed
Recommended For You
About ANAB Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ANAB | - | - |
AnaptysBio, Inc. |